Telomir Pharmaceuticals (Telomir Pharmaceuticals) Debt-to-Equity : 0.03 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Debt-to-Equity?

Telomir Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Telomir Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Telomir Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.44 Mil. Telomir Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Telomir Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

TELO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.03 Max: 0.03
Current: 0.03

During the past 3 years, the highest Debt-to-Equity Ratio of Telomir Pharmaceuticals was 0.03. The lowest was 0.03. And the median was 0.03.

TELO's Debt-to-Equity is ranked better than
81.84% of 1074 companies
in the Biotechnology industry
Industry Median: 0.15 vs TELO: 0.03

Telomir Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Telomir Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Debt-to-Equity Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Equity

0.03

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-	0.13	0.61	0.03

Competitive Comparison of Telomir Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Telomir Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telomir Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Debt-to-Equity falls into.

Telomir Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Telomir Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.101	+	0)	/	3.438
	=	0.03

Telomir Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.101	+	0)	/	3.438
	=	0.03

Telomir Pharmaceuticals (NAS:TELO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Telomir Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024